Carolinas Wealth Consulting’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-277
Closed -$86.2K 39
2025
Q1
$86.2K Sell
277
-9
-3% -$2.66K 0.02% 267
2024
Q4
$74.5K Sell
286
-20
-7% -$5.93K 0.01% 302
2024
Q3
$98.3K Sell
306
-95
-24% -$31.1K 0.02% 266
2024
Q2
$125K Sell
401
-9
-2% -$2.64K 0.02% 227
2024
Q1
$117K Buy
410
+6
+1% +$1.76K 0.02% 238
2023
Q4
$116K Sell
404
-10
-2% -$2.73K 0.03% 219
2023
Q3
$106K Sell
414
-751
-64% -$187K 0.03% 210
2023
Q2
$259K Sell
1,165
-341
-23% -$79.1K 0.05% 154
2023
Q1
$364K Buy
1,506
+215
+17% +$52.8K 0.08% 122
2022
Q4
$339K Buy
1,291
+115
+10% +$30.8K 0.08% 124
2022
Q3
$265K Buy
1,176
+42
+4% +$10.2K 0.07% 129
2022
Q2
$276K Sell
1,134
-55
-5% -$13.5K 0.07% 121
2022
Q1
$288K Sell
1,189
-141
-11% -$32.4K 0.06% 134
2021
Q4
$299K Buy
1,330
+330
+33% +$69.6K 0.07% 134
2021
Q3
$213K Buy
1,000
+24
+2% +$5.52K 0.05% 152
2021
Q2
$238K Sell
976
-589
-38% -$145K 0.05% 150
2021
Q1
$389K Buy
1,565
+38
+2% +$9.07K 0.09% 101
2020
Q4
$351K Buy
1,527
+248
+19% +$57.2K 0.09% 104
2020
Q3
$325K Buy
1,279
+725
+131% +$180K 0.11% 85
2020
Q2
$131K Buy
+554
New +$126K 0.05% 129

Other funds holding AMGN

Carolinas Wealth Consulting's AMGN Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of Amgen (AMGN) in Q2 2025, closing a stake of 277 shares — an estimated $86.2K sold.

Carolinas Wealth Consulting first reported a position in AMGN in Q2 2020 and held it in 20 quarters. The position peaked at $389K in Q1 2021. 2,851 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.

  • Carolinas Wealth Consulting reported no remaining Amgen position as of Q2 2025 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 277 Amgen shares in Q2 2025, an estimated $86.2K.
  • Carolinas Wealth Consulting first reported a position in Amgen in Q2 2020 and held it in 20 quarters.
  • Carolinas Wealth Consulting's Amgen position peaked at $389K in Q1 2021.
  • 2,851 funds tracked by Wall St. Rank held Amgen as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.